HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Antigens

Subscribe to New Research on Antigens

Share|Follow on Twitter

Substances that are recognized by the immune system and induce an immune reaction.

Also Known As:

Antigen

Networked: 102955 relevant articles (3377 outcomes, 9650 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Biological Factors: 1106
- Antigens: 102955

Experts

1.	Old, Lloyd J: 84 articles (02/2012 - 02/2002)
2.	Rosenberg, Steven A: 48 articles (10/2012 - 01/2002)
3.	Ferrone, Soldano: 44 articles (06/2012 - 05/2003)
4.	Jungbluth, Achim A: 43 articles (12/2012 - 02/2002)
5.	Itoh, Kyogo: 37 articles (09/2012 - 03/2002)
6.	Ritter, Gerd: 35 articles (02/2012 - 04/2002)
7.	Chen, Yao-Tseng: 35 articles (01/2012 - 04/2002)
8.	Gnjatic, Sacha: 32 articles (12/2012 - 08/2002)
9.	Romero, Pedro: 31 articles (02/2012 - 02/2002)
10.	Restifo, Nicholas P: 29 articles (07/2012 - 09/2002)

Related Diseases

1.	Infection 04/01/2009 - "In this study, we evaluated the protective efficacy of immunizing mice with caseinolytic protease (ClpP) protein antigen whose gene sequences were shown to be highly conserved in different strains of Streptococcus pneumoniae in an invasive-disease model (intraperitoneal infection model), and protection against invasive challenge with 12 different serotypes of S. " 08/01/1998 - "b) Immunological study: detection of circulating antigen on the 3rd, 5th, 7th and 9th day p.i. The results showed that IL-2 was most effective when administered before and after infection in the form of significant reduction in parasitic count, least number of living tachyzoites, significant reduction in the death rate of infected mice and delayed appearance of circulating antigen with reduction in its level." 12/01/1992 - "Direct detection of respiratory syncytial (RS) virus antigen in nasopharyngeal secretions (NPS) provides the most rapid diagnostic test for RS infection, but more sensitive methods might be more beneficial in the study of virus shedding. " 11/01/2012 - "Screening patients for subclinical cryptococcal infection at the time of entry into antiretroviral therapy programs using cryptococcal antigen (CRAG) immunoassays is highly effective in identifying patients at risk of developing CM, allowing these patients to then be targeted with "preemptive" therapy to prevent the development of severe disease. " 03/01/2010 - "Similarly, with the intranasal challenge models, (i) additive clearance of bacteria in lungs was observed for the combination of the three antigens and (ii) a combination vaccine conferred complete protection against intranasal infections of three of the four most common pneumococcal strains (serotypes 14, 19F, and 23F) and 80% protection for pneumococcal strain 6B. " Order ALL the reference details at left...
2.	Neoplasms (Cancer) 08/03/2010 - "Active immunization using tumor antigen-loaded dendritic cells holds promise for the adjuvant treatment of cancer to eradicate or control residual disease, but so far, most dendritic cell trials have been performed in end-stage cancer patients with high tumor loads. " 02/01/1987 - "In our own studies two types of approaches were also effective with the highly metastatic mouse tumor line ESb which carries a weak tumor associated antigen. " 06/01/2007 - "The Ab/SA conjugate yielding the best tumor uptake and tumor-to-normal organ ratios of radioactivity varied depending on the target antigen expression on the cell line used, with 1F5/SA and Lym-1/SA yielding the most promising results overall. " 01/01/2006 - "For this reason, DC-based immunization has been shown to be highly effective in eliciting CTL responses to viruses and tumor-associated antigens. " 06/15/2004 - "The results show that the targeting of antigen to DCs in this way is highly effective at inducing immunity and protection against the tumor, with protection being at least partially dependent on the eosinophil chemokine eotaxin." Order ALL the reference details at left...
3.	Hepatitis B 12/01/1978 - "Eight of ten in the hepatitis B antigen-postive group cleared their antigen and had complete clinical recovery. " 07/01/2001 - "In adults at risk for a reduced response to hepatitis B vaccination [i.e., older adults (>/=40), the obese, males, and smokers], the triple antigen vaccine produced a significantly greater percentage of protected subjects (P < 0.001) and higher geometric mean titre (P < 0.001). " 07/01/2002 - "Sustained serological clearance of hepatitis B e antigen was associated with activation of CD4 positive HBV-specific T-cell reactivity and were of T-helper 1. Hence combination therapy with immunomodulatory agents and nucleoside analogues should be explored." 12/01/1993 - "Delayed clearance of hepatitis B e antigen occurred more frequently in nonresponders who had elevated pretreatment serum transaminase levels. " 12/01/1993 - "Twenty-eight (28%) nonresponders had sustained clearance of hepatitis B e antigen during follow-up. " Order ALL the reference details at left...
4.	Melanoma (Melanoma, Malignant) 05/01/1988 - "The results showed that 5-azadCyd was effective in inducing antigen expression in both systems whereas HU was effective (and equally so) only in the human melanoma cell line system. " 05/01/1987 - "The chimeric antibody, but not the mouse L6 antibody, is effective against a melanoma line expressing small amounts of the L6 antigen. " 08/01/1985 - "However, a melanoma cell line that expresses minimal levels of GD3 on 13% of the cells shows insignificant lysis by MB3.6 by either of these two mechanisms, suggesting that a threshold level of antigen expression may be required for effective in vitro cytolysis. " 05/01/2005 - "Although MVA-hTyr provides a safe and effective antigen-delivery system, it does not elicit a measurable immune response to its transgene product in patients with stage II melanoma after repeated combined intradermal and subcutaneous vaccination. " 01/01/2007 - "To study the anti-melanoma immunity efficacy of Ag85B antigen gene therapy in vivo. " Order ALL the reference details at left...
5.	Malaria 01/01/2009 - "It is likely that apart from differences in study methodologies, differences in exposure among study subjects within each study and brevity of antibody responses to malaria antigen are important sources of the variation in protective efficacy of anti-malaria immune responses mentioned above. " 01/01/2010 - "Cytotoxic T lymphocytes (CTL) directed against Plasmodium falciparum-derived antigens are shown to play an important role for the protection against malaria. " 11/01/2008 - "Cytotoxic T lymphocytes (CTL) directed against Plasmodium falciparum-derived antigens were shown to play an important role for the protection against malaria. " 01/01/2008 - "Antigen-specific antibody-mediated immune responses play an important role in natural protection against clinical malaria, but conflicting estimates of this association have emerged from immuno-epidemiological studies in different geographical settings. " 01/01/2006 - "Nevertheless, together the data have important implications for development of an effective malaria vaccine since the selection of appropriate Plasmodium antigens and/or adjuvants, targeting innate immune responses involving DCs, may provide optimal protection against malaria. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Antibodies
2.	Antigens
3.	DNA (Deoxyribonucleic Acid)
4.	Hepatitis B e Antigens
5.	Vaccines
6.	Immunoglobulin G (IgG)
7.	Hepatitis B Surface Antigens (HBsAg)
8.	Monoclonal Antibodies
9.	Lamivudine (3TC)
10.	Immunoglobulin M (IgM)

Related Therapies and Procedures

1.	Immunotherapy
2.	Drug Therapy (Chemotherapy)
3.	Transplantation (Transplant Recipients)
4.	Transplants (Transplant)
5.	Heterologous Transplantation (Xenotransplantation)

blog comments powered by Disqus

TREATMENT OPTIONS
for Infection,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 17293 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$24.95 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$490.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>